Detection of BRAFV600E Biomarker In Patients With Colorectal Cancer Using Immunohistochemical Techniques / Clinico-Pathological Study
DOI:
https://doi.org/10.32007/jfacmedbagdad.6411888Keywords:
Keyword: CRC : colorectal cancer BRAF : v-raf murine sarcoma viral oncogene homolog B1Abstract
Background :
Colorectal cancer (CRC) is the 4th common gastrointestinal cancer. (BRAFV600E) is a member of RAF family of serine/threonine protein kinases that function to regulate the (MAPK) / (ERK) pathway. BRAFV600E mutated CRC are associated with right-sided primary tumors, older women and high-grade tumors.
Aims of the study:
Study the immunohistochemical expression of BRAFV600E biomarker in a sample of Iraqi patients with colorectal cancer and the correlation of BRAFV600E expression with other clinicopathological variables such as patient's age and tumor grade.
Materials and Methods :
in this prospective study a total of 90 colorectal cases of a sample of Iraqi patients were collected from teaching labs of AL-Yarmouk Teaching Hospital including 60 cases of colorectal carcinoma and 30 cases of colorectal adenoma.
Result: BRAFV600E biomarker was positive in 16.6% of colorectal carcinoma group and negative in colorectal adenoma group.
Conclusions:
BRAF expression was higher in older patients ages & higher tumor stages and there is no expression of BRAFV600E in adenoma cases.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Dr.seror Alrubaiaee, Dr. Thaeer Al-taee
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.